Nexus NeuroTech Ventures

Founded in 2023 by Jordi Parramon, PhD and William Marks, MD and with the addition of Jon Lundt, PhD and John Propst, PhD, MBA, the firm brings a deep commitment to developing technologies to help those with neurodegenerative, neuropsychiatric, and neurodevelopmental disorders, such as Parkinson’s disease, bipolar disorder, and autism spectrum disorder. Adjacent to these sentinel disorders are many other brain disorders that are also within scope for Nexus NeuroTech Ventures. We’re building a portfolio to support technology that spans disease diagnosis and management, providing a holistic approach to brain disorders. We seek to invest in approaches spanning less invasive to more invasive medical technology-based treatment interventions, software- and hardware-based diagnostic technology, data platforms supporting clinical trials and clinical care, and tools directed at clinical research and clinical care.